Associations Between Polygenic Risk Score Loading, Psychosis Liability, and Clozapine Use Among Individuals With Schizophrenia
-
Published:2023-02-01
Issue:2
Volume:80
Page:181
-
ISSN:2168-622X
-
Container-title:JAMA Psychiatry
-
language:en
-
Short-container-title:JAMA Psychiatry
Author:
Lin Bochao D.1234, Pinzón-Espinosa Justo4567, Blouzard Elodie4, van der Horst Marte Z.48, Okhuijsen-Pfeifer Cynthia4, van Eijk Kristel R.4, Guloksuz Sinan19, Peyrot Wouter J.1011, Luykx Jurjen J.1248, Hasan Alkomiet12, Wagner Elias12, Pantelis Christos12, Everall Ian P.12, Ayhan Y.12, Babaoğlu M. O.12, Bak Maarten12, Alink Wouter12, Beld E12, Bouhuis A12, Edlinger M12, Erdoğan I .M.12, Gutwinski Stefan12, Hallikainen Tero12, Jeger-land E12, Lähteenvuo Markku12, de Koning Mariken B.12, Morgenroth Carla12, Müderrisoğlu A.12, Oviedo-Salcedo Tatiana12, Schreiter Stefanie12, Repo-Tiihonen Eila12, Tuppurainen Heli12, Veereschild Mike12, Veerman Selene R.T.12, de Vos M12, Cohen Dan12, Bogers Jan P.A.M.12, Anıl Yağcıoğlu A.E.12, Tiihonen Jari12, Ripke Stephan12, Bousman Chad A.12, Van Beek H12, Okhuijsen-Pfeifer Cynthia12, van der Horst Marte12, van Eijk Kristel12, Ertuğrul A.12, Yoca G.12, Görlitz T.12, Grootens K.P.12, Leucht Stefan12, Narang A.12, Schneider-Thoma J.12, Kahn René S.12, Bekema Erwin12, Kleymann Phillip12, Luykx Jurjen J.12, Alizadeh Behrooz Z.12, van Amelsvoort Therese12, Cahn Wiepke12, de Haan Lieuwe12, Schirmbeck Frederike12, Simons Claudia J.P.12, van Os Jim12, Rutten Bart12, van Winkel Ruud12,
Affiliation:
1. Department of Psychiatry and Neuropsychology, Maastricht University Medical Center, Maastricht, the Netherlands 2. Research Institute Brainclinics, Brainclinics Foundation, Nijmegen, the Netherlands 3. Department of Preventive Medicine, Institute of Biomedical Informatics, Bioinformatics Center, School of Basic Medical Sciences, Henan University, Kaifeng, China 4. Department of Psychiatry, University Medical Center Utrecht, Utrecht University, Brain Center Rudolf Magnus, Utrecht, the Netherlands 5. Sant Pau Mental Health Group, Institut d’Investigació Biomèdica Sant Pau (IBB-Sant Pau), Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona (UAB), Barcelona, Catalonia, Spain 6. Department of Medicine, School of Medicine, University of Barcelona, Barcelona, Spain 7. Department of Clinical Psychiatry, School of Medicine, University of Panama, Panama City, Panama 8. GGNet Mental Health, Warnsveld, the Netherlands 9. Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut 10. Department of Psychiatry, Amsterdam UMC, Amsterdam, the Netherlands 11. Department of Complex Trait Genetics, Center for Neurogenomics and Cognitive Research, Amsterdam Neuroscience, VU University Amsterdam, Amsterdam, the Netherlands 12. for the Genetic Risk and Outcome of Psychosis (GROUP) and Clozapine International Consortium (CLOZIN) Investigators
Abstract
ImportancePredictors consistently associated with psychosis liability and course of illness in schizophrenia (SCZ) spectrum disorders (SSD), including the need for clozapine treatment, are lacking. Longitudinally ascertained medication use may empower studies examining associations between polygenic risk scores (PRSs) and pharmacotherapy choices.ObjectiveTo examine associations between PRS-SCZ loading and groups with different liabilities to SSD (individuals with SSD taking clozapine, individuals with SSD taking other antipsychotics, their parents and siblings, and unrelated healthy controls) and between PRS-SCZ and the likelihood of receiving a prescription of clozapine relative to other antipsychotics.Design, Setting, and ParticipantsThis genetic association study was a multicenter, observational cohort study with 6 years of follow-up. Included were individuals diagnosed with SSD who were taking clozapine or other antipsychotics, their parents and siblings, and unrelated healthy controls. Data were collected from 2004 until 2021 and analyzed between October 2021 and September 2022.ExposuresPolygenic risk scores for SCZ.Main Outcomes and MeasuresMultinomial logistic regression was used to examine possible differences between groups by computing risk ratios (RRs), ie, ratios of the probability of pertaining to a particular group divided by the probability of healthy control status. We also computed PRS-informed odd ratios (ORs) for clozapine use relative to other antipsychotics.ResultsPolygenic risk scores for SCZ were generated for 2344 participants (mean [SD] age, 36.95 years [14.38]; 994 female individuals [42.4%]) who remained after quality control screening (557 individuals with SSD taking clozapine, 350 individuals with SSD taking other antipsychotics during the 6-year follow-up, 542 parents and 574 siblings of individuals with SSD, and 321 unrelated healthy controls). All RRs were significantly different from 1; RRs were highest for individuals with SSD taking clozapine (RR, 3.24; 95% CI, 2.76-3.81; P = 2.47 × 10−46), followed by individuals with SSD taking other antipsychotics (RR, 2.30; 95% CI, 1.95-2.72; P = 3.77 × 10−22), parents (RR, 1.44; 95% CI, 1.25-1.68; P = 1.76 × 10−6), and siblings (RR, 1.40; 95% CI, 1.21-1.63; P = 8.22 × 10−6). Polygenic risk scores for SCZ were positively associated with clozapine vs other antipsychotic use (OR, 1.41; 95% CI, 1.22-1.63; P = 2.98 × 10−6), suggesting a higher likelihood of clozapine prescriptions among individuals with higher PRS-SCZ.Conclusions and RelevanceIn this study, PRS-SCZ loading differed between groups of individuals with SSD, their relatives, and unrelated healthy controls, with patients taking clozapine at the far end of PRS-SCZ loading. Additionally, PRS-SCZ was associated with a higher likelihood of clozapine prescribing. Our findings may inform early intervention and prognostic studies of the value of using PRS-SCZ to personalize antipsychotic treatment.
Publisher
American Medical Association (AMA)
Subject
Psychiatry and Mental health
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|